title: Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
abstract: Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy. Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV. ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.
authors.affiliation: Division of Clinical Pharmacy, University of California, San Francisco 94143-0622.
authors.forename: F T
authors.initials: FT
authors.lastname: Aweeka
authors.forename: J G
authors.initials: JG
authors.lastname: Gambertoglio
authors.forename: C
authors.initials: C
authors.lastname: van der Horst
authors.forename: R
authors.initials: R
authors.lastname: Raasch
authors.forename: M A
authors.initials: MA
authors.lastname: Jacobson
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000378:metabolism*; D000328:Adult; D000998:Antiviral Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D017245:Foscarnet / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016655:HIV Core Protein p24 / Q000032:analysis / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015215:Zidovudine / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D016655:HIV Core Protein p24; D017245:Foscarnet; D015215:Zidovudine